IRIDEX Corporation  

(Public, NASDAQ:IRIX)   Watch this stock  
Find more results for iridex
10.02
+0.18 (1.83%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.75 - 10.02
52 week 6.41 - 11.28
Open 10.00
Vol / Avg. 8,434.00/21,972.00
Mkt cap 98.78M
P/E 10.20
Div/yield     -
EPS 0.98
Shares 9.86M
Beta 1.13
Inst. own 54%
Apr 29, 2015
Q1 2015 IRIDEX Corp Earnings Release (Estimated) Add to calendar
Mar 5, 2015
Q4 2014 IRIDEX Corp Earnings Call - Webcast
Mar 5, 2015
Q4 2014 IRIDEX Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2015
Net profit margin 74.41% 23.45%
Operating margin 8.35% 6.04%
EBITD margin - 7.02%
Return on average assets 94.50% 26.59%
Return on average equity 118.44% 33.69%
Employees 106 -
CDP Score - -

Address

1212 Terra Bella Ave
MOUNTAIN VIEW, CA 94043-1824
United States - Map
+1-650-9404700 (Phone)
+1-650-9404710 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The main focus of the Company is on ophthalmology business. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases. The Company�s ophthalmology business includes repair, servicing and extended service contracts for its laser systems, and a capital component, consisting of the laser consoles combined with durable delivery devices (laser systems). Its laser consoles consist of IQ products, which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems and OcuLight products including OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems.

Officers and directors

Will M. Moore Jr. Chairman of the Board, Interim President and Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
James H. Mackaness Chief Financial Officer, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Ronald T. Steckel Vice President - Operations
Bio & Compensation  - Reuters
George R Marcellino PhD Director
Bio & Compensation  - Reuters
Scott A. Shuda Director
Age: 48
Bio & Compensation  - Reuters
Sanford Fitch Independent Director
Age: 73
Bio & Compensation  - Reuters
Ruediger Naumann-Etienne Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters